| Description | This product is a neutralizing antibody that binds to Crimean-Congo Hemorrhagic Fever virus. The antibody neutralizes CCHFV by blocking Gc homotrimerization in the endosome and preventing membrane fusion. this mAb displays highly potent cross-clade neutralization to CCHFV, which makes it a viable candidate for clinical development. |
| Clonality | Monoclonal |
| Host Species | Human |
| Target Species | CCHFV |
| Isotype | IgG1 |
| Expression Species | HEK293F or CHO cell line |
| Conjugation | Unconjugated |
| Purity | >95% |
| Endotoxin | <1 EU/mg |
| Form | Liquid |
| Purification | Protein A purified |
| Sterility | 0.2 μM filtered |
| Formulation | PBS, pH 7.4 |
| Preservation | No preservatives |
| Stabilizer | No stabilizers |
| Storage | Store at 4°C within one or two weeks. Store at -20°C for long term. Avoid repeated freeze/thaw cycles. Refer to the COA file for specifics. |
| Application | ELISA |
| ELISA | Enzyme-Linked Immunosorbent Assay Protocol |
| WB | Western Blot Protocol |
| FC | Flow Cytometry Protocol |
| Target | CCHFV |
| Alternative Name | Crimean-Congo Hemorrhagic Fever virus |
| Research Area | Infectious Disease |
| Related Disease | hemorrhage; myalgia; high fever |
